2 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Kari Wisinski: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Gedatolisib, Talazoparib - TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Kari Wisinski | 37 | 2019-04-17 | 2024-06-07 |
| Ribociclib and Bicalutamide in AR+ TNBC ribociclib, Bicalutamide - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Kari Wisinski | 37 | 2018-05-07 | 2026-01-02 |
Triple Negative Breast Neoplasms (2)
bicalutamide (1) · gedatolisib (1) · ribociclib (1) · talazoparib (1)
United States (2)